Preclinical data presented at Alzheimer’s Association International Conference (AAIC) 2021
Dr. Anders Sandberg, Chief Scientific Officer, presented data on the Company's monoclonal antibody, ALZ-201. The poster features preclinical data relating to Alzinova’s immunotherapy technology platform that specifically targets the oligomeric, neurotoxic forms of the amyloid-β peptide (Aβ) aggregates, which are considered to be the cause of Alzheimer’s disease.
The preclinical data support the continued development of Alzinova’s lead candidate, ALZ-101, which is further in development. The data were presented at the Alzheimer’s Association International Conference 2021 (AAIC) on 26 July.